Indian Immunologicals to invest Rs 75 crores to expand its Karkapatla Plant
Indian Immunologicals Ltd (IIL), a leading biologicals company, has announced the ground-breaking of a new Sterile Filling Facility (SFF) at its manufacturing plant in Phase III of Genome Valley, Karkapatla, Ranga Reddy District, Telangana. With this investment of Rs 75 crores in the upcoming filling facility, Indian Immunologicals Limited expects to increase its capacity to supply lifesaving vaccines such as the Anti Rabies Vaccine (ARV).
The new state-of-the-art facility expected to be ready later next year. The sterile facility is equipped with hi-end filling equipment from the world’s best manufacturers, in line with the requirements of the nature of work handled at the plant.
Dr. K Anand Kumar, Managing Director, Indian Immunologicals Limited, said, “IIL has a long history of supplying vaccines critical to public health. We are constantly striving to make the vaccines affordable and accessible to reach the benefits of preventive healthcare to a maximum number of people. The expansion at Karkapatla plant is in line with our mission and will help meet the growing requirements of critical vaccines.”
Dr. Prasanna Deshpande, Deputy Managing Director, Indian Immunologicals Limited, added, “Currently there are reports of shortages of anti-rabies vaccine in the country. Investment in a new sterile filling facility shows that IIL is committed to expanding manufacturing capacity to meet unmet public health needs in India. With supply from this facility, IIL will continue to be the largest rabies vaccine manufacturer in the country.”